Precision BioSciences Stock (NASDAQ: DTIL)

Precision BioSciences (NASDAQ:DTIL) Stock, Quote.Headers.trade-ideas

Precision BioSciences

Precision BioSciences Inc is a genome editing company dedicated to improving life through its genome editing platform, ARCUS. It leverages ARCUS in the development of its product candidates, which are designed to treat human diseases and provide food and agricultural solutions. The ARCUS is also unique in its relatively small size which potentially allows delivery to a wider range of cells and tissues using viral and non-viral gene delivery methods.

DTIL

Biotech

News

Health Care

Movers

Trading Ideas

General

Precision BioSciences reports early PBGENE-HBV trial data showing safety and antiviral activity in chronic Hepatitis B patients, with more results expected in 2025.

Precision BioSciences Touts Encouraging Initial Safety And Antiviral Activity Of Hepatitis B Treatment Candidate

Gene Sequencing

Analyst Color

Upgrades

Price Target

Analyst Ratings

Precision BioSciences gains momentum as iECURE reports positive ECUR-506 data, and analysts forecast significant HBV program-driven stock growth.

Precision BioSciences&#39; Gene Editing Platform Has Differentiated Mechanism, And Is Potentially Competitive: Analyst

Palantir, Salesforce, Okta, Meta, And Tesla: Why These 5 Stocks Are On Investors' Radars Today

Pre-Market Outlook

Markets

AVNW

BAER

CLDI

CURE PHARMA HLDG CORP by CURE Pharmaceutical Holding Corp.

CURR

EWCZ

IGMS

INTZ

MVST

Penguin Solutions, Inc. - Ordinary Shares

PENG

SENS

SILO

STAI

VINP

VMAR

XXII

ZCAR

Why Zoomcar Shares Are Trading Higher By Over 40%; Here Are 20 Stocks Moving Premarket

Precision BioSciences, Inc. - Common Stock

Precision BioSciences Inc

Press Releases

Precision BioSciences Reports Third Quarter 2024 Financial Results and Provides Business Update

Precision BioSciences Highlights Preclinical Data and Outlines Design of First-in-Human Clinical Trial for PBGENE-HBV for Treatment of Chronic Hepatitis B

Precision BioSciences to Participate in Upcoming November Investor Conferences

Precision BioSciences Receives Approval in Hong Kong to Expand PBGENE-HBV Phase 1 ELIMINATE-B Trial for the Treatment of Chronic Hepatitis B

iECURE Reports Complete Clinical Response in First Infant Dosed with its In Vivo Gene Editing Candidate ECUR-506 in an Ongoing Phase 1/2 Clinical Trial in Ornithine Transcarbamylase (OTC) Deficiency

Precision BioSciences Announces Complete Clinical Response in First Infant Dosed by Partner iECURE in Ongoing Phase 1/2 Clinical Trial in Ornithine Transcarbamylase (OTC) Deficiency

Precision BioSciences Strengthens Senior Leadership Team to Drive Multiple In Vivo Gene Editing Programs

Precision BioSciences Announces Initial Safety and Antiviral Activity of PBGENE-HBV in the ELIMINATE-B Clinical Trial

Precision BioSciences Announces Oral Presentation at the 2025 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference

iECURE to Present Initial Data from Phase 1/2 OTC-HOPE Clinical Trial in Ornithine Transcarbamylase Deficiency at ACMG Annual Clinical Genetics Meeting

Alterity Therapeutics Limited - American Depositary Shares

Alterity Therapeutics

Actinium Pharmaceuticals, Inc. (Delaware) Common Stock

Actinium Pharma

Atara Biotherapeutics, Inc. - Common Stock

Atara Biotherapeutics

bluebird bio

Barinthus Biotherapeutics plc - American Depositary Shares

Barinthus Biotherapeutics

Celularity

Clene

Coeptis Therapeutics Holdings, Inc. - Common Stock

Coeptis Therapeutics

Dyadic International, Inc. - Common Stock

Dyadic International

Estrella Immunopharma, Inc. - Common Stock

Estrella Immunopharma

FibroBiologics

Forte Biosciences

Kala Bio

LakeShore Biopharma Co., Ltd - Ordinary Shares

LakeShore Biopharma

Lantern Pharma

MAIA Biotechnology

OS Therapies

Ovid Therapeutics

Prelude Therapeutics Incorporated - Common Stock

Prelude Therapeutics

Rein Therapeutics

Spero Therapeutics

Surrozen

Tempest Therapeutics, Inc. - Common Stock

Tempest Therapeutics

vTv Therapeutics Inc. - Class A Common Stock

vTv Therapeutics

Xilio Therapeutics

HC Wainwright & Co.

BMO Capital

Guggenheim

BTIG

Goldman Sachs

Comments

Precision BioSciences

Precision BioSciences (NASDAQ:DTIL) Stock, Quote.Headers.trade-ideas

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga